Hanall Biopharma Co.,Ltd (009420.KS)
KRW 27800.0
(-0.18%)
KRW 27800.0
(-0.18%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 134.9 Billion | 109.99 Billion | 101.59 Billion | 88.6 Billion | 108.45 Billion | 91.83 Billion |
| Cost of Revenue | 59.87 Billion | 48.02 Billion | 41.26 Billion | 37.95 Billion | 45.67 Billion | 42.81 Billion |
| Gross Profit | 75.03 Billion | 61.97 Billion | 60.33 Billion | 50.65 Billion | 62.78 Billion | 49.02 Billion |
| Operating Expenses | 71.98 Billion | 60.46 Billion | 50.23 Billion | 44.71 Billion | 45.69 Billion | 43.55 Billion |
| Selling, General and Administrative Expenses | 48.03 Billion | 23.23 Billion | 20.52 Billion | 17.37 Billion | 16.81 Billion | 13.81 Billion |
| Research and Development Expenses | 23.94 Billion | 16.49 Billion | 10.46 Billion | 9.31 Billion | 10.05 Billion | 10.54 Billion |
| Other Expenses | - | 20.73 Billion | 19.24 Billion | 18.02 Billion | 18.82 Billion | 246.41 Million |
| Cost and Expenses | 131.85 Billion | 108.48 Billion | 91.49 Billion | 82.66 Billion | 91.36 Billion | 86.36 Billion |
| Operating Income | 3.05 Billion | 2.31 Billion | 10.09 Billion | 8.48 Billion | 17.08 Billion | 5.47 Billion |
| Interest Expense | 63.86 Million | 21.87 Million | 25.48 Million | 16 Million | 13.75 Million | 600.00 |
| Income Tax Expense | -306.07 Million | 1.67 Billion | -194.04 Million | -539.21 Million | -1.71 Billion | 696.3 Million |
| Earnings before Tax | 3.2 Billion | 1.92 Billion | 8.7 Billion | 19.22 Billion | 17.45 Billion | 3.99 Billion |
| Net Income | 3.5 Billion | 251.47 Million | 8.89 Billion | 19.76 Billion | 19.17 Billion | 3.3 Billion |
| Earnings Per Share Basic | 69.21 | 4.95 | 173.74 | 386.19 | 374.67 | 64.48 |
| Earnings Per Share Diluted | 69.21 | 4.95 | 173.74 | 386.19 | 374.67 | 64.48 |
| Weighted Average Shares Outstanding | 50.69 Million | 50.81 Million | 51.2 Million | 51.17 Million | 51.17 Million | 51.17 Million |
| Weighted Average Shares Outstanding (Diluted) | 50.69 Million | 50.81 Million | 51.2 Million | 51.17 Million | 51.17 Million | 51.17 Million |
| Gross Margin | 0.56 | 0.56 | 0.59 | 0.57 | 0.58 | 0.53 |
| EBIT Margin | 0.04 | 0.05 | 0.13 | 0.13 | 0.21 | 0.13 |
| Profit Margin | 0.03 | 0.00 | 0.09 | 0.22 | 0.18 | 0.04 |
| EBITDA | 4.99 Billion | 4.55 Billion | 11.45 Billion | 8.82 Billion | 20.18 Billion | 7.46 Billion |
| Earnings Before Tax Margin | 0.02 | 0.02 | 0.10 | 0.10 | 0.16 | 0.06 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 36.84 Billion | 31.59 Billion | 34.09 Billion | 31.71 Billion | 134.9 Billion | 32.96 Billion |
| Cost of Revenue | - | 16.04 Billion | 15.8 Billion | 17.45 Billion | 61.24 Billion | 15.42 Billion |
| Gross Profit | 36.84 Billion | 15.55 Billion | 18.28 Billion | 14.26 Billion | 73.66 Billion | 17.54 Billion |
| Operating Expenses | 36.41 Billion | 34.65 Billion | 33.97 Billion | 18.68 Billion | 71.92 Billion | -17.45 Billion |
| Selling, General and Administrative Expenses | - | 12.25 Billion | 12.9 Billion | 13.13 Billion | - | 17.45 Billion |
| Research and Development Expenses | - | 6.2 Billion | 5.09 Billion | 5.39 Billion | - | 4.55 Billion |
| Other Expenses | -36.41 Billion | -34.65 Billion | -33.97 Billion | -154.14 Million | -669.45 Million | -34.91 Billion |
| Cost and Expenses | 36.41 Billion | 34.65 Billion | 33.97 Billion | 36.13 Billion | 133.16 Billion | 15.42 Billion |
| Operating Income | 430 Million | -3.05 Billion | 119 Million | -4.41 Billion | 1.74 Billion | 91.21 Million |
| Interest Expense | - | - | 18.43 Million | 18.04 Million | 63.86 Million | 14.93 Million |
| Income Tax Expense | 314 Million | -3.08 Billion | 285 Million | -1.76 Billion | -306.07 Million | 191.96 Million |
| Earnings before Tax | 536 Million | -6.41 Billion | -38 Million | -4.59 Billion | 3.27 Billion | 510.78 Million |
| Net Income | 222 Million | -3.32 Billion | -323 Million | -2.86 Billion | 3.5 Billion | 318.81 Million |
| Earnings Per Share Basic | 4.25 | -65.57 | -6.37 | -56.48 | - | 6.29 |
| Earnings Per Share Diluted | 4.25 | -65.57 | -6.37 | -56.48 | - | 6.29 |
| Weighted Average Shares Outstanding | 52.24 Million | 50.69 Million | 50.69 Million | 50.69 Million | 50.69 Million | 50.69 Million |
| Weighted Average Shares Outstanding (Diluted) | 52.24 Million | 50.69 Million | 50.69 Million | 50.69 Million | 50.69 Million | 50.69 Million |
| Gross Margin | 1.00 | 0.49 | 0.54 | 0.45 | 0.55 | 0.53 |
| EBIT Margin | 0.01 | -0.10 | 0.00 | -0.11 | - | 0.53 |
| Profit Margin | 0.01 | -0.11 | -0.01 | -0.09 | 0.03 | 0.01 |
| EBITDA | 430 Million | -3.05 Billion | 119 Million | -3.55 Billion | - | 17.54 Billion |
| Earnings Before Tax Margin | 0.01 | -0.10 | 0.00 | -0.14 | 0.01 | 0.00 |
002298
RBL
3902
CDTX
JOSTS
JAIBALAJI